PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-05-01

Date Title Company
01-May-2025 BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements ACCESS Newswire
01-May-2025 Venture Medical Announces Strategic Partnership With Plasmacure to Bring Proven Cold Plasma Therapy System for Wound Healing to the U.S. Market ACCESS Newswire
01-May-2025 The Silent Trailblazer: Dr. Azriel Hirschfeld, Oncology's Best-Kept Secret ACCESS Newswire
01-May-2025 PharmaNest Launches FibroMAP, the First Single-Fiber Phenotypic Tool for the Study of Fibrosis Across Biological Models and Indications Newswire
01-May-2025 Camgenium and Cardiac Tech Partner to Improve Patient Outcomes Post-Cardiac Surgery with Pace-Protect System Camgenium
01-May-2025 Alzheimer’s Family of Friends Foundation Offers Urgent Financial Relief for Families Affected by Dementia ACCESS Newswire
01-May-2025 UK Company, Stablepharma Ltd, enters Phase 1 Clinical Trials with world-first Fridge-Free Tetanus & Diphtheria Vaccine Stablepharma Ltd
01-May-2025 First patient enrolled in Phase 1 clinical trial of Akiram’s cancer drug candidate AKIR001 Akiram Therapeutics
01-May-2025 PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference PureTech
01-May-2025 Astoriom appoints Ryan Smith as Global Head of Sales Astoriom
01-May-2025 Netsmart Secures #1 Ranking in Geriatrics and Gerontology EHR & Practice Management in 2025 Black Book Survey ACCESS Newswire
01-May-2025 PharmaNest Launches FibroMAP, the First Single-Fiber Phenotypic Tool for the Study of Fibrosis Across Biological Models and Indications ACCESS Newswire
01-May-2025 FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain OKYO Pharma Limited
01-May-2025 Clinigen announces key executive appointments to drive the next phase of growth and deliver increased investor value Clinigen
01-May-2025 Leqembi® ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease (AD) in the UK is validated for evaluation by the MHRA Eisai
01-May-2025 Bespak achieves sustainability milestone with first life cycle assessment for pressurised Metered Dose Inhaler valve Bespak
01-May-2025 Enara Bio Strengthens Senior Leadership with Key Executive and Board Appointments Alongside Acceleration of Multiple T-Cell Engager Programs Enara Bio
01-May-2025 Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia Nxera
01-May-2025 Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations Nxera
01-May-2025 Preliminary unaudited results for the year ended 31 December 2024 Commercial progress and order book growth Cambridge Cognition Holdings plc